The impact of geopolitics in clinical trial location with Scott Schliebner

In this episode, Sylvain Berthelot welcomes Scott Schliebner, Global Head of Drug Development Consulting at Novotech. With over 25 years of experience across CRO leadership roles, Scott brings a unique perspective on how global politics and shifting market dynamics are influencing where – and how – clinical trials are run.

Together, Sylvain and Scott explore the growing uncertainty created by political change, regulatory shifts, and economic pressures, and how these factors are shaping sponsor strategies. From the rise of early-phase studies in Australia and New Zealand, to the diversification of phase III trial geographies, they discuss why sponsors are increasingly reluctant to rely on a U.S.-only model.

Scott explains how geopolitical factors such as trade tensions, FDA staffing challenges, and evolving diversity guidance impact trial planning, and why sponsors must think proactively about data representativeness across regions. The conversation also highlights the scientific – rather than political – benefits of conducting multi-regional trials, ensuring that new medicines reach the patients who need them most.

Tune in to discover how sponsors are mitigating risk, balancing timelines and costs, and navigating the new realities of trial globalization.